Indian J Cancer 2012, 49:169–175 PubMedCrossRef 38 Faivre S, Kal

Indian J Cancer 2012, 49:169–175.PubMedCrossRef 38. Faivre S, Kalla S, Cvitkovic E, Bourdon O, Hauteville D, Dourte LM, Bensmaïne MA, Itzhaki M, Marty M, Extra JM: Oxaliplatin and paclitaxel combination

in patients with platinum-pretreated ovarian carcinoma: an investigator-originated compassionate-use experience. Ann Oncol 1999, 10:1125–1128.PubMedCrossRef 39. Pectasides D, Pectasides M, Farmakis D, Gaglia A, Koumarianou A, Nikolaou M, Koumpou M, Kountourakis P, Papaxoinis G, Mitrou Erlotinib cell line P, Economopoulos T, Raptis SA: Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study. Gynecol Oncol 2004, 95:165–172.PubMedCrossRef 40. Rosa DD, Awada A, Mano MS, Selleslags J, Lebrun F, Gil T, Piccart MJ, D’Hondt V: Oxaliplatin/5fluorouracil-based chemotherapy was active and well tolerated

in heavily pretreated patients with ovarian carcinoma. Arch Gynecol Obstet 2008, 278:457–462.PubMedCrossRef 41. Polyzos A, Kosmas C, Toufexi H, Malamos N, Lagadas A, Kosmidis C, Ginopoulos P, Ziras N, selleck kinase inhibitor Kandilis K, Georgoulias V: Docetaxel in combination with irinotecan (CPT-11) in platinum-resistant paclitaxel-pretreated ovarian cancer. Anticancer Res 2005, 25:3559–3564.PubMed 42. Tsubamoto H, Kawaguchi R, Ito K, Shiozaki T, Takeuchi S, Itani Y, Arakawa A, Tabata T, Toyoda S: Phase II study

of carboplatin and weekly irinotecan combination chemotherapy in recurrent ovarian cancer: a Kansai clinical oncology group study (KCOG0330). Anticancer Res 2013, 33:1073–1079.PubMed 43. Levitt NC, Propper DJ, Madhusudan S, Braybrooke JP, Echeta C, Te Poele R, Davies SL, Flanagan E, Hickson ID, Joel S, Ganesan TS: Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer. Br J Cancer 2005, 93:60–69.PubMedCrossRef 44. Bolis G, Parazzini F, Scarfone G, of Villa A, Amoroso M, Rabaiotti E, Polatti A, Reina S, Pirletti E: Paclitaxel vs epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and -resistant ovarian cancer. Gynecol Oncol 1999, 72:60–64.PubMedCrossRef 45. Buda A, Floriani I, Rossi R, Colombo N, Torri V, Conte PF, Fossati R, Ravaioli A, Mangioni C: Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the Mario Negri Institute, Milan, G.O.N.O. (Gruppo Oncologico Nord Ovest) group and I.O.R. (Istituto Oncologico Romagnolo) group. Br J Cancer 2004, 90:2112–2117.PubMed 46.

Comments are closed.